Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”

This letter to the editor reports subsequent rechallenge with peptide receptor radionuclide therapy (PRRT) in a patient with pancreatic neuroendocrine tumor bearing BRCA1 mutation previously treated with PRRT.

Detalles Bibliográficos
Autores principales: Zhu, Mojun, Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177096/
https://www.ncbi.nlm.nih.gov/pubmed/35403684
http://dx.doi.org/10.1093/oncolo/oyac068
_version_ 1784722818774073344
author Zhu, Mojun
Bekaii-Saab, Tanios
author_facet Zhu, Mojun
Bekaii-Saab, Tanios
author_sort Zhu, Mojun
collection PubMed
description This letter to the editor reports subsequent rechallenge with peptide receptor radionuclide therapy (PRRT) in a patient with pancreatic neuroendocrine tumor bearing BRCA1 mutation previously treated with PRRT.
format Online
Article
Text
id pubmed-9177096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91770962022-06-09 Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors” Zhu, Mojun Bekaii-Saab, Tanios Oncologist Letters to the Editor This letter to the editor reports subsequent rechallenge with peptide receptor radionuclide therapy (PRRT) in a patient with pancreatic neuroendocrine tumor bearing BRCA1 mutation previously treated with PRRT. Oxford University Press 2022-04-11 /pmc/articles/PMC9177096/ /pubmed/35403684 http://dx.doi.org/10.1093/oncolo/oyac068 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Zhu, Mojun
Bekaii-Saab, Tanios
Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title_full Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title_fullStr Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title_full_unstemmed Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title_short Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
title_sort update to “homologous recombination repair defect may predict treatment response to peptide receptor radionuclide therapy for neuroendocrine tumors”
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177096/
https://www.ncbi.nlm.nih.gov/pubmed/35403684
http://dx.doi.org/10.1093/oncolo/oyac068
work_keys_str_mv AT zhumojun updatetohomologousrecombinationrepairdefectmaypredicttreatmentresponsetopeptidereceptorradionuclidetherapyforneuroendocrinetumors
AT bekaiisaabtanios updatetohomologousrecombinationrepairdefectmaypredicttreatmentresponsetopeptidereceptorradionuclidetherapyforneuroendocrinetumors

Ejemplares similares